Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)

Core Viewpoint - Nektar Therapeutics reported a quarterly loss of $0.15 per share, missing the Zacks Consensus Estimate of a loss of $0.13 per share, and showing an improvement from a loss of $0.22 per share a year ago [1] Financial Performance - The company posted revenues of $29.18 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 25.23%, but showing an increase from year-ago revenues of $23.89 million [2] - Nektar's earnings surprise was -15.38%, and it had previously reported a loss of $0.18 per share against an expected loss of $0.23 per share, resulting in a surprise of 21.74% [1][3] Stock Performance - Nektar shares have declined approximately 11.9% since the beginning of the year, compared to a decline of 5.3% for the S&P 500 [3] - The company's current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of $20.72 million, and for the current fiscal year, it is -$0.80 on revenues of $76.8 million [7] Industry Outlook - The Medical - Drugs industry, to which Nektar belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Nektar's stock performance [5][6]